Sirtex Medical Supports The First Pilot Study Evaluating SIR-Spheres(R) Microspheres In Combination With Bevacizumab And Chemotherapy As A First Line Treatment For Metastatic Colorectal Cancer

LAKE FORREST, Ill.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, is pleased to announce its support of a clinical study evaluating the safety of SIR-Spheres® microspheres when administered with bevacizumab, an anti-angiogenic agent, and chemotherapy as a first-line treatment for patients with colorectal cancer that has metastasized to the liver. The “FAST” trial will evaluate the concurrent administration of either FOLFOX6 or FOLFIRI and bevacizumab with Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres. Andrew Kennedy, M.D., co-medical director of Wake Radiology Oncology in Cary, N.C., will serve as principal investigator for the trial.

MORE ON THIS TOPIC